Topics

Polatuzumab Vedotin Offers a New Option for Refractory DLBCL

10:13 EDT 17 Oct 2019 | OncLive

Jeff Sharman, MD, discusses the current approval and potential future roles for polatuzumab vedotin-piiq (Polivy) in diffuse large B-cell lymphoma.

Original Article: Polatuzumab Vedotin Offers a New Option for Refractory DLBCL

NEXT ARTICLE

More From BioPortfolio on "Polatuzumab Vedotin Offers a New Option for Refractory DLBCL"

Quick Search